» Articles » PMID: 25329329

Autosomal Dominant Immune Dysregulation Syndrome in Humans with CTLA4 Mutations

Abstract

The protein cytotoxic T lymphocyte antigen-4 (CTLA-4) is an essential negative regulator of immune responses, and its loss causes fatal autoimmunity in mice. We studied a large family in which five individuals presented with a complex, autosomal dominant immune dysregulation syndrome characterized by hypogammaglobulinemia, recurrent infections and multiple autoimmune clinical features. We identified a heterozygous nonsense mutation in exon 1 of CTLA4. Screening of 71 unrelated patients with comparable clinical phenotypes identified five additional families (nine individuals) with previously undescribed splice site and missense mutations in CTLA4. Clinical penetrance was incomplete (eight adults of a total of 19 genetically proven CTLA4 mutation carriers were considered unaffected). However, CTLA-4 protein expression was decreased in regulatory T cells (Treg cells) in both patients and carriers with CTLA4 mutations. Whereas Treg cells were generally present at elevated numbers in these individuals, their suppressive function, CTLA-4 ligand binding and transendocytosis of CD80 were impaired. Mutations in CTLA4 were also associated with decreased circulating B cell numbers. Taken together, mutations in CTLA4 resulting in CTLA-4 haploinsufficiency or impaired ligand binding result in disrupted T and B cell homeostasis and a complex immune dysregulation syndrome.

Citing Articles

The intestinal microbiome and metabolome discern disease severity in cytotoxic T-lymphocyte-associated protein 4 deficiency.

Chandrasekaran P, Krausz M, Han Y, Mitsuiki N, Gabrysch A, Noltner C Microbiome. 2025; 13(1):51.

PMID: 39934899 PMC: 11817180. DOI: 10.1186/s40168-025-02028-7.


The effect of HLA genotype on disease onset and severity in CTLA-4 insufficiency.

Posadas-Cantera S, Mitsuiki N, Emmerich F, Patino V, Lorenz H, Neth O Front Immunol. 2025; 15():1447995.

PMID: 39835139 PMC: 11744039. DOI: 10.3389/fimmu.2024.1447995.


Harnessing the biology of regulatory T cells to treat disease.

Wardell C, Boardman D, Levings M Nat Rev Drug Discov. 2024; 24(2):93-111.

PMID: 39681737 DOI: 10.1038/s41573-024-01089-x.


Congenital T-cell activation impairs transitional-to-follicular B-cell maturation in humans.

Allard-Chamard H, Hillier K, Ramseier M, Bertocchi A, Kaneko N, Premo K Blood Adv. 2024; 9(3):520-532.

PMID: 39626280 PMC: 11814514. DOI: 10.1182/bloodadvances.2024013267.


Case report: Pediatric patient with severe clinical course of CTLA-4 insufficiency treated with HSCT.

Drabko K, Zarychta J, Kowalczyk A, Cienkusz M Front Immunol. 2024; 15:1484467.

PMID: 39624103 PMC: 11609194. DOI: 10.3389/fimmu.2024.1484467.


References
1.
Barzaghi F, Passerini L, Bacchetta R . Immune dysregulation, polyendocrinopathy, enteropathy, x-linked syndrome: a paradigm of immunodeficiency with autoimmunity. Front Immunol. 2012; 3:211. PMC: 3459184. DOI: 10.3389/fimmu.2012.00211. View

2.
Bachmann M, Kohler G, Ecabert B, Mak T, Kopf M . Cutting edge: lymphoproliferative disease in the absence of CTLA-4 is not T cell autonomous. J Immunol. 1999; 163(3):1128-31. View

3.
McKenna A, Hanna M, Banks E, Sivachenko A, Cibulskis K, Kernytsky A . The Genome Analysis Toolkit: a MapReduce framework for analyzing next-generation DNA sequencing data. Genome Res. 2010; 20(9):1297-303. PMC: 2928508. DOI: 10.1101/gr.107524.110. View

4.
van Dongen J, Langerak A, Bruggemann M, Evans P, Hummel M, Lavender F . Design and standardization of PCR primers and protocols for detection of clonal immunoglobulin and T-cell receptor gene recombinations in suspect lymphoproliferations: report of the BIOMED-2 Concerted Action BMH4-CT98-3936. Leukemia. 2003; 17(12):2257-317. DOI: 10.1038/sj.leu.2403202. View

5.
Tabares P, Berr S, Romer P, Chuvpilo S, Matskevich A, Tyrsin D . Human regulatory T cells are selectively activated by low-dose application of the CD28 superagonist TGN1412/TAB08. Eur J Immunol. 2013; 44(4):1225-36. DOI: 10.1002/eji.201343967. View